SYS-CON MEDIA Authors: Doug Masi, Mat Mathews, PR.com Newswire, David Smith, Tim Crawford

News Feed Item

BioSyent to Present at the 2014 Bloom Burton & Co. Healthcare Investor Conference

TORONTO, ONTARIO -- (Marketwired) -- 06/13/14 -- BioSyent Inc. ("BioSyent") (TSX VENTURE:RX) is pleased to announce that CEO Rene Goehrum will be making a presentation at the 2014 Bloom Burton & Co. Healthcare Investor Conference at 4:30pm (ET), June 18, 2014 at the Toronto Board of Trade. Mr. Goehrum will provide an overview of the Company and its corporate activities.

Mr. Goehrum will be available for 1:1 meetings on the day of his presentation.These meetings can be arranged via the conference organizers http://www.bloomburton.com/conference/.

BioSyent also announces the grant of 17,031 incentive stock options to certain employees and officers of the Company. These incentive stock options are exercisable at a price of $7.45 up to June 12, 2024.

For a direct market quote (15 minutes delay) for the TSX Venture Exchange and other Company financial information please visit www.tmxmoney.com.

About BioSyent Inc.

Listed on the Toronto Venture Exchange under the trading symbol "RX", BioSyent is a profitable growth oriented specialty pharmaceutical company which searches the globe to in-license or acquire innovative pharmaceutical products that have been successfully developed, are safe and effective, and have a proven track record of improving the lives of patients and supporting the healthcare professionals that treat them.

Once a product of interest has been found, BioSyent then acquires the exclusive rights to the product and manages it through the Canadian governmental regulatory approval process. Once approved, BioSyent markets the product throughout Canada.

At the date of this press release the Company had 13,801,195 shares issued and outstanding.

More Stories By Marketwired .

Copyright © 2009 Marketwired. All rights reserved. All the news releases provided by Marketwired are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving in a public database, redistributing via a computer network or in a printed form.